Integrating clinical and rna-seq findings in a mare with recurrent endocrinopathic laminitis linked to equine metabolic syndrome.

This case report describes a young mare with equine metabolic syndrome whose insulin-driven laminitis kept recurring and ultimately proved fatal despite diet changes, analgesia, an SGLT2 inhibitor, and later pergolide. After necropsy was non-diagnostic, pancreatic RNA sequencing showed clear differences versus a healthy horse, highlighting potential molecular mechanisms behind treatment-refractory disease and the need for more research.

What the condition is and why it matters

• Equine metabolic syndrome (EMS) features insulin dysregulation (basal and/or post-prandial hyperinsulinemia), regional or generalized adiposity, and a high risk of hyperinsulinemia-associated laminitis (HAL).
• HAL arises when prolonged or exaggerated insulin elevations trigger lamellar failure in the hoof; it is a leading cause of pain, loss of function, and euthanasia in affected horses.
• Standard management emphasizes low nonstructural carbohydrate (NSC) feeding, weight control, controlled exercise (when safe), and hoof care; adjunct pharmacologic options aim to reduce insulin or blunt glycemic excursions.

Case summary and clinical course

• Patient: 5-year-old mare with recurrent endocrinopathic laminitis attributable to EMS; young age underscores that severe EMS is not limited to older horses.
• Initial response: Low-NSC diet and conventional therapy (analgesia, hoof support, management) provided only transient relief, indicating persistent insulin dysregulation.
• Insulin-lowering strategy: An SGLT2 inhibitor was started to reduce resting insulin by promoting glucosuria and lowering glycemia; clinical improvement followed for several months.
• Deterioration: In October 2024, the mare experienced the most severe bout of laminitis despite ongoing management; pergolide mesylate was added (to address a possible endocrinopathy contributing to insulin dysregulation), and analgesics were resumed, but the condition progressed.
• Outcome: Euthanasia in November 2024 due to worsening, refractory laminitis; necropsy did not reveal a definitive structural cause for the uncontrolled metabolic disease.

Rationale for the therapies used

• Low-NSC diet: Reduces post-prandial glycemic and insulinemic spikes that precipitate HAL.
• Analgesia and hoof support: Limit pain and mechanical strain while lamellae are compromised; cryotherapy and careful farriery are standard supportive measures.
• SGLT2 inhibitor: Lowers renal glucose reabsorption, decreasing blood glucose and secondarily basal insulin; in horses, this class has shown promise for reducing hyperinsulinemia and laminitis risk, though long-term data and optimal dosing are still emerging.
• Pergolide mesylate: A dopamine agonist used for pituitary pars intermedia dysfunction (PPID); although PPID is uncommon at 5 years, seasonal ACTH surges and subclinical pars intermedia activity can exacerbate insulin dysregulation in some horses, prompting an empirical trial when HAL worsens.

Why this case became refractory: plausible contributors

• Severity of insulin dysregulation: Some EMS horses exhibit extreme basal hyperinsulinemia and exaggerated insulin secretion to minimal carbohydrate intake, overwhelming standard diet-based control.
• Seasonality: Autumnal increases in ACTH and pasture NSC can markedly worsen insulin dynamics and HAL risk, even without overt PPID.
• Pain–stress hormones: Ongoing pain and stress elevate catecholamines and cortisol, antagonizing insulin action and perpetuating a vicious cycle.
• Individual biology: Genetic predisposition, adipokine profile (e.g., low adiponectin), altered hepatic insulin clearance, or intrinsic pancreatic beta-cell abnormalities can make responses to therapy unpredictable.
• Therapeutic limits: While SGLT2 inhibitors reduce insulin, counter-regulatory responses (e.g., glucagon rise), variable drug exposure, dehydration risk, or owner management constraints can blunt real-world efficacy.

Necropsy and RNA-seq: what was done and why it matters

• Necropsy: No gross or histopathologic lesion was identified that explained the uncontrolled hyperinsulinemia or refractory HAL, directing attention to molecular mechanisms.
• Pancreatic RNA sequencing: Transcriptomes from the mare’s pancreas were compared with a healthy control, revealing clear differences in gene expression.
• Value of RNA-seq here: Provides hypothesis-generating insights into pathways related to insulin secretion, beta-cell stress, islet signaling, inflammation, and metabolic regulation that may not be evident on routine pathology.
• Technical caution: A single-case versus single-control comparison lacks statistical power; observed differences should be treated as exploratory (useful for pathway patterns, not definitive gene-level claims).

How to interpret “clear transcriptomic differences” in this context

• Potentially informative pathways: Changes might involve genes governing stimulus–secretion coupling (ion channels, exocytosis), ER stress and unfolded protein response, incretin/hormone receptor signaling, oxidative stress, immune signaling, or islet cell identity and proliferation.
• Functional implications: Upregulation of secretory machinery or impaired feedback inhibition could favor persistent hyperinsulinemia; conversely, stress-response signatures may indicate maladaptive beta-cell strain in the face of chronic metabolic load.
• Tissue composition effects: Differences could reflect shifts in islet-to-acinar proportion or immune cell infiltration; bulk RNA-seq conflates cell types, so single-cell or spatial methods would help disentangle this.
• Next analytic steps: Pathway enrichment, gene-set testing, and comparison with known EMS/insulin dysregulation signatures (where available) can refine hypotheses for targeted validation (qPCR, IHC, functional assays).

Clinical and research implications

• For clinicians: Some EMS horses may remain at high laminitis risk despite best-practice diet and supportive care; early, sustained insulin-lowering strategies and vigilant seasonal management are critical, but failure can still occur.
• Therapeutic strategy gaps: Optimal choice, timing, and combination of pharmacologic agents (e.g., SGLT2 inhibitors, metformin, TZDs not commonly used in horses, pergolide in select cases) require controlled trials focused on clinically meaningful endpoints (insulin metrics and laminitis outcomes).
• Biomarkers: Molecular markers from blood or hair follicles reflecting pancreatic stress or dysregulated insulin secretion could help identify horses at risk for refractory HAL.
• Pathophysiology refinement: Integrating transcriptomics with endocrine testing (basal and dynamic insulin, adiponectin, ACTH), metabolomics, and imaging could reveal distinct EMS subtypes (e.g., secretion-dominant vs clearance-deficient) informing personalized care.

Strengths and limitations of the report

• Strengths: Detailed real-world course of a young, severely affected EMS case; integration of clinical timeline with post-mortem molecular profiling to move beyond descriptive pathology.
• Limitations: Single-case design; absence of replicated RNA-seq samples or longitudinal molecular data; inability to assign causality from transcript differences; potential confounding by agonal events or post-mortem interval.

Key takeaways

• Refractory HAL can occur in EMS even with appropriate diet, hoof care, and insulin-lowering therapy, underscoring the condition’s heterogeneity.
• SGLT2 inhibition may improve insulin control but does not eliminate risk in all horses, particularly during seasonal high-risk periods.
• Pancreatic RNA-seq differences versus a healthy control suggest intrinsic islet biology may drive treatment resistance in some EMS cases, warranting larger, controlled molecular studies.
• Future work should prioritize multi-omics cohorts, standardized therapeutic trials, and development of practical biomarkers to identify and manage high-risk, treatment-refractory EMS horses earlier.